Zydus Lifesciences Third Quarter 2025 Earnings: EPS Beats Expectations

Zydus Lifesciences (NSE:ZYDUSLIFE) Third Quarter 2025 Results

Key Financial Results

• Revenue: ₹52.7b (up 17% from 3Q 2024).
• Net income: ₹10.2b (up 33% from 3Q 2024).
• Profit margin: 19% (up from 17% in 3Q 2024). The increase in margin was driven by higher revenue.
• EPS: ₹10.17 (up from ₹7.59 in 3Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zydus Lifesciences EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 12%.

Looking ahead, revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are up 5.7% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Zydus Lifesciences (1 is potentially serious!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.